Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.54 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ILK | Q13418 | 1/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 2/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.44 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.44 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | PAK4 | O96013 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15020489 | 0.80 | MAPT (0.66) | LMNAMAPTTDP1KDM4EGAA | |
| SCHEMBL1248084 | 0.80 | LMNA (0.66) | LMNAMAPTTDP1MAPK14KDM4E | |
| SCHEMBL1245491 | 0.80 | LMNA (0.66) | LMNAMAPTTDP1KDM4EGAA | |
| SCHEMBL13516147 | 0.79 | LMNA (0.55) | LMNAMAPTTDP1KDM4EILK | |
| SCHEMBL1246534 | 0.79 | LMNA (0.59) | LMNAMAPTTDP1KDM4EILK | |
| SCHEMBL461478 | 0.79 | LMNA (1.00) | LMNAMAPTTDP1KDM4EILK | |
| SCHEMBL13516120 | 0.78 | LMNA (0.62) | LMNAMAPTTDP1KDM4EILK | |
| SCHEMBL17730627 | 0.78 | LMNA (0.58) | LMNAMAPTTDP1KDM4EILK | |
| SCHEMBL16534777 | 0.78 | LMNA (0.68) | LMNAMAPTTDP1MAPK14MAPK13 | |
| SCHEMBL12651076 | 0.76 | AKT2 (0.66) | MAPK14MAPK13MAPK12MAPK11TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | BIOENERGENIX LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | BIOENERGENIX LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-9969741-B2 | Pyrazolotriazines as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2018-05-15 | — | — | US | disclosed |
| US-9969741-B2 | Pyrazolotriazines as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2018-05-15 | — | — | US | disclosed |
| EP-2957562-B1 | PYRAZOLOTRIAZINES AS INHIBITORS OF NUCLEASES | UNIV MASARYKOVA (CZ) | 2017-12-20 | — | — | EP | disclosed |
| US-20170197966-A1 | PYRAZOLOTRIAZINES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2017-07-13 | — | — | US | disclosed |
| US-20170197966-A1 | PYRAZOLOTRIAZINES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2017-07-13 | — | — | US | disclosed |
| EP-2957562-A1 | Pyrazolotriazines as inhibitors of nucleases | Masarykova univerzita (CZ) | 2015-12-23 | — | — | EP | disclosed |
| WO-2015192817-A1 | PYRAZOLOTRIAZINES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2015-12-23 | — | — | WO | disclosed |
| WO-2012149157-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120277224-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277224-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277224-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120165335-A1 | CDK INHIBITORS | CURIS, INC. | 2012-06-28 | — | — | US | disclosed |
| WO-2010075542-A1 | CDK INHIBITORS | CURIS, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277224-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | LMNA 1114/4885MAPT 3629/4885TDP1 2483/4885 |
| US-20120165335-A1 | CDK INHIBITORS | CDK3, CDK6, CDKL1 | LMNA 2371/4885MAPT 2025/4885TDP1 490/4885 |
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | PASK, PDXK, PANK2 | LMNA 1114/4885MAPT 3629/4885TDP1 2483/4885 |
| US-20170197966-A1 | PYRAZOLOTRIAZINES AS INHIBITORS OF NUCLEASES | DNASE1, TDP1, RNASEH1 | LMNA 286/4885MAPT 732/4885TDP1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.